Abstract：
UNASSIGNED: This study aims to evaluate the treatment approaches and locoregional patterns for Adenoid cystic carcinoma (ACC) in the breast, which is an uncommon malignant tumor with limited clinical data.
UNASSIGNED: A total of 93 patients diagnosed with primary ACC in the breast between 1992 and 2022 were collected from multi-institutions. All patients underwent surgical resection, including breast-conserving surgery (BCS) or total mastectomy (TM). The recurrence patterns and locoregional recurrence-free survival (LRFS) were assessed.
UNASSIGNED: Seventy-five patients (80.7%) underwent BCS, and 71 of them (94.7%) received post-operative radiation therapy (PORT). Eighteen patients (19.3%) underwent TM, with 5 of them (27.8%) also receiving PORT. With a median follow-up of 50 months, the LRFS rate was 84.2% at 5 years. Local recurrence (LR) was observed in 5 patients (5.4%) and 4 cases (80%) of the LR occurred in the tumor bed. Three of LR (3/75, 4.0%) had a history of BCS and PORT, meanwhile, two of LR (2/18, 11.1%) had a history of mastectomy. Regional recurrence occurred in 2 patients (2.2%), and both cases had a history of PORT with (n=1) and without (n=1) irradiation of the regional lymph nodes. Partial breast irradiation (p=0.35), BCS (p=0.96) and PORT in BCS group (p=0.33) had no significant association with LRFS.
UNASSIGNED: BCS followed by PORT was the predominant treatment approach for ACC of the breast and local recurrence mostly occurred in the tumor bed. The findings of this study suggest that partial breast irradiation might be considered for PORT in primary breast ACC.
UNASSIGNED: A total of 93 patients diagnosed with primary ACC in the breast between 1992 and 2022 were collected from multi-institutions. All patients underwent surgical resection, including breast-conserving surgery (BCS) or total mastectomy (TM). The recurrence patterns and locoregional recurrence-free survival (LRFS) were assessed.
UNASSIGNED: Seventy-five patients (80.7%) underwent BCS, and 71 of them (94.7%) received post-operative radiation therapy (PORT). Eighteen patients (19.3%) underwent TM, with 5 of them (27.8%) also receiving PORT. With a median follow-up of 50 months, the LRFS rate was 84.2% at 5 years. Local recurrence (LR) was observed in 5 patients (5.4%) and 4 cases (80%) of the LR occurred in the tumor bed. Three of LR (3/75, 4.0%) had a history of BCS and PORT, meanwhile, two of LR (2/18, 11.1%) had a history of mastectomy. Regional recurrence occurred in 2 patients (2.2%), and both cases had a history of PORT with (n=1) and without (n=1) irradiation of the regional lymph nodes. Partial breast irradiation (p=0.35), BCS (p=0.96) and PORT in BCS group (p=0.33) had no significant association with LRFS.
UNASSIGNED: BCS followed by PORT was the predominant treatment approach for ACC of the breast and local recurrence mostly occurred in the tumor bed. The findings of this study suggest that partial breast irradiation might be considered for PORT in primary breast ACC.
摘要：
■本研究旨在评估乳腺腺样囊性癌（ACC）的治疗方法和局部模式，这是一种罕见的恶性肿瘤，临床资料有限。
■从多机构收集了1992年至2022年间诊断为乳腺原发性ACC的总共93例患者。所有患者均行手术切除,包括保乳手术（BCS）或全乳房切除术（TM）。评估了复发模式和局部无复发生存率（LRFS）。
■75例患者（80.7%）接受BCS，其中71例(94.7%)接受了术后放射治疗(PORT)。18例患者（19.3%）接受TM，其中5人(27.8%)也接受了港口。中位随访时间为50个月，5年LRFS率为84.2%。其中5例(5.4%)出现局部复发(LR),4例(80%)发生在瘤床。三个LR(3/75，4.0%)有BCS和PORT的历史，同时,两个LR(2/18,11.1%)有乳房切除术史.2例(2.2%)发生局部复发,并且两个病例均有PORT病史，其中（n=1）和未（n=1）区域淋巴结照射。部分乳房照射（p=0.35），BCS组（p=0.96）和PORT（p=0.33）与LRFS无显著相关性。
■BCS和PORT是乳腺ACC的主要治疗方法，局部复发主要发生在瘤床。这项研究的结果表明，对于原发性乳腺ACC的PORT，可能考虑部分乳腺照射。
■从多机构收集了1992年至2022年间诊断为乳腺原发性ACC的总共93例患者。所有患者均行手术切除,包括保乳手术（BCS）或全乳房切除术（TM）。评估了复发模式和局部无复发生存率（LRFS）。
■75例患者（80.7%）接受BCS，其中71例(94.7%)接受了术后放射治疗(PORT)。18例患者（19.3%）接受TM，其中5人(27.8%)也接受了港口。中位随访时间为50个月，5年LRFS率为84.2%。其中5例(5.4%)出现局部复发(LR),4例(80%)发生在瘤床。三个LR(3/75，4.0%)有BCS和PORT的历史，同时,两个LR(2/18,11.1%)有乳房切除术史.2例(2.2%)发生局部复发,并且两个病例均有PORT病史，其中（n=1）和未（n=1）区域淋巴结照射。部分乳房照射（p=0.35），BCS组（p=0.96）和PORT（p=0.33）与LRFS无显著相关性。
■BCS和PORT是乳腺ACC的主要治疗方法，局部复发主要发生在瘤床。这项研究的结果表明，对于原发性乳腺ACC的PORT，可能考虑部分乳腺照射。
